Showing results (141-150 of 151) with videos related to
Sort By:
Pageof 16
Oncotarget|December 10, 2017
MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapyBrian H Kushner, Michael P LaQuaglia, Shakeel Modak, et al.International Journal of Cancer|August 21, 2023
Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapyBrian H Kushner, Michael P LaQuaglia, Fiorella Iglesias Cardenas, et al.Pediatric Blood & Cancer|November 9, 2022
Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastomaKathryn R Tringale, Suzanne L Wolden, Dana L Casey, et al.The Journal of Biological Chemistry|October 11, 1996
Interaction of phosphorylated FcepsilonRIgamma immunoglobulin receptor tyrosine activation motif-based peptides with dual and single SH2 domains of p72syk. Assessment of binding parameters and real time binding kineticsT Chen, B Repetto, R Chizzonite, et al.International Journal of Radiation Oncology, Biology, Physics|October 21, 2025
Local Control With Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results From a Prospective Clinical TrialChristopher B Jackson, Dana L Casey, Brian H Kushner, et al.Pediatrics|August 2, 2019
Local Anesthesia With General Anesthesia for Pediatric Bone Marrow ProceduresSara Zarnegar-Lumley, Katharine R Lange, Melissa D Mathias, et al.Journal of Neuro-Oncology|February 28, 2023
Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymomaKathryn R Tringale, Suzanne L Wolden, Matthias Karajannis, et al.Pediatric Blood & Cancer|July 5, 2024
Ovarian function in female survivors of high-risk neuroblastomaLauren Jimenez-Kurlander, Amelia DeRosa, Caroline E Kostrzewa, et al.European Journal of Cancer (Oxford, England : 1990)|March 14, 2025
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusionsAmi V Desai, Aditi Bagchi, Amy E Armstrong, et al.Neuro-Oncology|April 8, 2022
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)Ami V Desai, Giles W Robinson, Karen Gauvain, et al.Pageof 16